We present a case of Acremonium vertebral osteomyelitis that relapsed despite surgical debridement and prolonged treatment with liposomal amphotericin B, but which responded to voriconazole therapy. The report highlights the role of molecular diagnosis of rare fungal osteomyelitis. The patient was successfully treated with voriconazole.
was amplified by PCR using primers ITS1 and ITS4, which are specific for the internal transcribed spacer region, essentially as described elsewhere [1] . The resulting amplicon was reamplified using internal primers UNF1 and UNF2, specific for the ITS2 region [2] . The nested PCR product was digested with HaeIII endonuclease. PCR and restriction fragment-length polymorphism analysis revealed a restriction pattern (fragment lengths, 193 base pairs and 92 base pairs) compatible with that of Acremonium species when compared with a well-characterized strain from our laboratory collection. Confirmation of the identity of the pathogen was obtained by direct sequencing of the first amplicon. Comparative analysis of the nucleotide sequence of the internal transcribed spacer region revealed 99% homology to Acremonium strictum genogroup IV (GenBank accession number AY138486).
Therapy with oral voriconazole was started at a dosage of 400 mg administered twice per day, followed by 200 mg administered twice per day and continued for a total of 6 months. C-reactive protein levels returned to normal, and after 24 months of followup, the patient remains well.
Fungal osteomyelitis is a rare disease and generally presents in an indolent fashion. The incidence of fungal bone and joint disease is increasing because of an increase in the prevalence of factors predisposing to invasive fungal disease, such as the use of central venous catheters, use of broad-spectrum antibiotics, immunosuppression, and abdominal surgery [3] . Definitive diagnosis relies on bone culture or biopsy. The fungi reported as causative agents of osteomyelitis include Candida, Aspergillus, and Fusarium species; Scedosporium apiospermum; and endemic dimorphic fungi, including Histoplasma capsulatum, Blastomyces dermatitidis, and Coccidioides immitis; in addition, there have been 2 case reports of infection due to Acremonium species in a bone marrow transplant recipient [3] [4] [5] . Successful management of infection has traditionally consisted of therapy with amphotericin B in combination with surgical debridement.
There are several species of Acremonium that have been implicated in infections, including Acremonium falciforme, Acremonium kiliense, Acremonium strictum, and Acremonium recifei. These are filamentous, cosmopolitan fungi that are commonly isolated from plant debris and soil. They grow rapidly. Colonies are white to pale gray and are velvety, becoming cottony as they mature and loose hyphae overgrow. Acremonium species possess fine and narrow septate hyphae. Although Acremonium species usually grow slowly in Sabouraud dextrose agar, the structural properties of conidia vary depending on the species [6, 7] . In this case, the failure to grow from bone culture is probably at- tributable to specimen handling and emphasizes the usefulness of molecular identification when culture fails to identify the pathogen.
Acremonium species are mainly environmental saprophytes. Their clinical relevance is most commonly as the cause of foot mycetomas or corneal infections following penetrating injuries. Acremonium species are being increasingly recognized as opportunistic pathogens that cause a variety of infections in immunocompromised patients. Two cases of osteomyelitis have been reported, 1 of which occurred in an adult with osteomyelitis of the calvarium from whom A. kiliense was isolated and who was successfully treated with amphotericin B and ketoconazole therapy in addition to craniectomy [8] . The second case occurred in a 9-year-old immunocompromised patient who was receiving corticosteroid treatment and who underwent splenectomy and bone marrow transplantation for autoimmune hemolytic anemia with subsequent tacrolimus administration. This patient had tibial osteomyelitis caused by A. strictum and was treated with surgical debridement and 12 days of therapy with amphotericin B followed by voriconazole [9] .
The scarcity of Acremonium infection makes the optimal antifungal therapy difficult to establish. Amphotericin B, ketoconazole, itraconazole, fluconazole, 5-fluorocytosine, voriconazole, and combinations of these antifungal drugs have been tried with variable success. Amphotericin B has been most commonly used in treating patients with serious infections, and it has been recommended on the basis of in vitro antifungal susceptibility testing [10] . In a recent report, 2 patients who experienced failure of amphotericin B treatment were successfully treated with voriconazole therapy [11] .
The risk factor for invasive fungal infection in our patient was diabetes mellitus. This case highlights the importance of a sequence-based diagnostic method in the identification of fungi and in facilitating the differentiation of the pathogen from species with similar morphological characteristics. The benefit of establishing an accurate identification is further supported by the fact that the organism may sometimes be resistant to amphotericin B, which is a point that is made more relevant by the availability of several treatment options. Voriconazole therapy seems to be effective and is easier to administer over the prolonged course needed to eradicate Acremonium osteomyelitis.
